Tharick Ali Pascoal

Tharick Ali Pascoal

Auto-generated profile, based on publicly available information

Tharick Ali Pascoal

Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TPTharick A. Pascoal
Tharick A. Pascoal
ABAndrea L. Benedet
Andrea L. Benedet
NANicholas J. Ashton
Nicholas J. Ashton
MKMin Su Kang
Min Su Kang
JTJoseph Therriault
Joseph Therriault
PRPedro Rosa-Neto
Pedro Rosa-Neto

28 April 2021 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
NSNatalia M. Lyra e Silva
Natalia M. Lyra e Silva
RGRafaella A. Gonçalves
Rafaella A. Gonçalves
TPTharick A. Pascoal
Tharick A. Pascoal
RLRicardo A. S. Lima-Filho
Ricardo A. S. Lima-Filho
ERElisa de Paula França Resende
Elisa de Paula França Resende
FFFernanda G. De Felice
Fernanda G. De Felice
Alzheimer’s disease (AD) is associated with memory impairment and altered peripheral metabolism. Mounting evidence indicates that abnormal signaling in a brain-periphery metabolic axis plays a role in AD pathophysiology. The activation of pro-inflammatory pathways in the brain, including the interleukin-6 (IL-6) pathway, comprises a potential point of convergence between memory dysfunction and metabolic alterations in AD that remains to be better explored. Using T2-weighted magnetic resonance imaging (MRI), we observed signs of probable inflammation in the hypothalamus and in the hippocampus of AD patients when compared to cognitively healthy control subjects. Pathological examination of post-mortem AD hypothalamus revealed the presence of hyperphosphorylated tau and tangle-like structures, as well as parenchymal and vascular amyloid deposits surrounded by astrocytes. T2 hyperintensities on MRI positively correlated with plasma IL-6, and both correlated inversely with cognitive performance and hypothalamic/hippocampal volumes in AD patients. Increased IL-6 and suppressor of cytokine signaling 3 (SOCS3) were observed in post-mortem AD brains. Moreover, activation of the IL-6 pathway was observed in the hypothalamus and hippocampus of AD mice. Neutralization of IL-6 and inhibition of the signal transducer and activator of transcription 3 (STAT3) signaling in the brains of AD mouse models alleviated memory impairment and peripheral glucose intolerance, and normalized plasma IL-6 levels. Collectively, these results point to IL-6 as a link between cognitive impairment and peripheral metabolic alterations in AD. Targeting pro-inflammatory IL-6 signaling may be a strategy to alleviate memory impairment and metabolic alterations in the disease.

29 May 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
BBBruna Bellaver
Bruna Bellaver
GPGuilherme Povala
Guilherme Povala
PFPamela C. L. Ferreira
Pamela C. L. Ferreira
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
DLDouglas T. Leffa
Douglas T. Leffa
TPTharick A. Pascoal
Tharick A. Pascoal
An unresolved question for the understanding of Alzheimer’s disease (AD) pathophysiology is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pathology and, consequently, clinical deterioration. In vitro evidence suggests that reactive astrocytes unleash Aβ effects in pathological tau phosphorylation. Here, in a biomarker study across three cohorts (n = 1,016), we tested whether astrocyte reactivity modulates the association of Aβ with tau phosphorylation in CU individuals. We found that Aβ was associated with increased plasma phosphorylated tau only in individuals positive for astrocyte reactivity (Ast+). Cross-sectional and longitudinal tau–positron emission tomography analyses revealed an AD-like pattern of tau tangle accumulation as a function of Aβ only in CU Ast+individuals. Our findings suggest astrocyte reactivity as an important upstream event linking Aβ with initial tau pathology, which may have implications for the biological definition of preclinical AD and for selecting CU individuals for clinical trials.

25 April 2022 in Nature Aging
Verified
Journal Article
Open access
PDF file
JTJoseph Therriault
Joseph Therriault
TPTharick A. Pascoal
Tharick A. Pascoal
FLFiroza Z. Lussier
Firoza Z. Lussier
CTCécile Tissot
Cécile Tissot
MCMira Chamoun
Mira Chamoun
PRPedro Rosa-Neto
Pedro Rosa-Neto
Gold-standard diagnosis of Alzheimer’s disease (AD) relies on histopathological staging systems. Using the topographical information from [18F]MK6240 tau positron-emission tomography (PET), we applied the Braak tau staging system to 324 living individuals. We used PET-based Braak stage to model the trajectories of amyloid-β, phosphorylated tau (pTau) in cerebrospinal fluid (pTau181, pTau217, pTau231 and pTau235) and plasma (pTau181 and pTau231), neurodegeneration and cognitive symptoms. We identified nonlinear AD biomarker trajectories corresponding to the spatial extent of tau-PET, with modest biomarker changes detectable by Braak stage II and significant changes occurring at stages III–IV, followed by plateaus. Early Braak stages were associated with isolated memory impairment, whereas Braak stages V–VI were incompatible with normal cognition. In 159 individuals with follow-up tau-PET, progression beyond stage III took place uniquely in the presence of amyloid-β positivity. Our findings support PET-based Braak staging as a framework to model the natural history of AD and monitor AD severity in living humans.

18 May 2022 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
TKThomas K. Karikari
Thomas K. Karikari
NANicholas Ashton
Nicholas Ashton
GBGunnar Brinkmalm
Gunnar Brinkmalm
WBWagner S. Brum
Wagner S. Brum
ABAndréa L. Benedet
Andréa L. Benedet
HZHenrik Zetterberg
Henrik Zetterberg

31 March 2017 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
KNKok Pin Ng
Kok Pin Ng
TPTharick A. Pascoal
Tharick A. Pascoal
SMSulantha Mathotaarachchi
Sulantha Mathotaarachchi
JTJoseph Therriault
Joseph Therriault
MKMin Su Kang
Min Su Kang
PRPedro Rosa-Neto
Pedro Rosa-Neto
18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of 18F-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, particularly given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). Here, we tested the effects of MAO-B inhibition on 18F-THK5351 brain uptake using PET and autoradiography. Eight participants (five mild cognitive impairment, two Alzheimer’s disease, and one progressive supranuclear palsy) had baseline 18F-AZD4694 and 18F-THK5351 scans in order to quantify brain amyloid and PHF load, respectively. A second 18F-THK5351 scan was conducted 1 week later, 1 h after a 10-mg oral dose of selegiline. Three out of eight patients also had a third 18F-THK5351 scan 9–28 days after the selegiline administration. The primary outcome measure was standardized uptake value (SUV), calculated using tissue radioactivity concentration from 50 to 70 min after 18F-THK5351 injection, normalizing for body weight and injected radioactivity. The SUV ratio (SUVR) was determined using the cerebellar cortex as the reference region. 18F-THK5351 competition autoradiography studies in postmortem tissue were conducted using 150 and 500 nM selegiline. At baseline, 18F-THK5351 SUVs were highest in the basal ganglia (0.64 ± 0.11) and thalamus (0.62 ± 0.14). In the post-selegiline scans, the regional SUVs were reduced on average by 36.7% to 51.8%, with the greatest reduction noted in the thalamus (51.8%) and basal ganglia (51.4%). MAO-B inhibition also reduced 18F-THK5351 SUVs in the cerebellar cortex (41.6%). The SUVs remained reduced in the three patients imaged at 9–28 days. Tissue autoradiography confirmed the effects of MAO-B inhibition on 18F-THK5351 uptake. These results indicate that the interpretation of 18F-THK5351 PET images, with respect to tau, is confounded by the high MAO-B availability across the entire brain. In addition, the heterogeneous MAO-B availability across the cortex may limit the interpretation of 18F-THK5351 scans using reference region methods.